1
|
Massaro F, Pavone V, Stefani PM, Botto B, Pulsoni A, Patti C, Cantonetti M, Visentin A, Scalzulli PR, Rossi A, Galimberti S, Cimminiello M, Gini G, Musso M, Sorio M, Arcari A, Zilioli VR, Bari A, Mannina D, Fabbri A, Pietrantuono G, Annibali O, Tafuri A, Prete E, Mulè A, Barbolini E, Marcheselli L, Luminari S, Merli F. BRENTUXIMAB VEDOTIN CONSOLIDATION AFTER AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR HODGKIN LYMPHOMA: A REAL‐LIFE EXPERIENCE BY FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.65_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Massaro
- PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia Modena Italy
| | - V. Pavone
- Department of Hematology and Bone Marrow Transplant Hospital Card. G. Panico Tricase Italy
| | - P. M. Stefani
- Hematology Unit, General Hospital Ca' Foncello Treviso Italy
| | - B. Botto
- Division of Hematology, Città della Salute e della Scienza Hospital and University Turin Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine, Sapienza University Rome Italy
| | - C. Patti
- Division of Hematology, Azienda Villa Sofia‐Cervello Palermo Italy
| | - M. Cantonetti
- Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata Rome Italy
| | - A. Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine (DIMED) University of Padua Padua Italy
| | - P. R. Scalzulli
- Department of Hematology Casa Sollievo della Sofferenza San Giovanni Rotondo Italy
| | - A. Rossi
- Hematology Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy
| | - S. Galimberti
- Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa Pisa Italy
| | | | - G. Gini
- Division of Hematology, Azienda Ospedaliera Universitaria Ospedali Riuniti Ancona Italy
| | - M. Musso
- Department of Oncology, Hematology and BMT Unit Casa di Cura La Maddalena Palermo Italy
| | - M. Sorio
- Department of Clinical and Experimental Medicine, Hematology and Bone Marrow Transplant Unit Verona Italy
| | - A. Arcari
- Hematology Unit, Ospedale Guglielmo da Saliceto Piacenza Italy
| | - V. R. Zilioli
- Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milan Italy
| | - A. Bari
- Dipartimento di Scienze Mediche e Chirurgiche Materno‐Infantili e dell'Adulto Università di Modena e Reggio Emilia Modena Italy
| | - D. Mannina
- Unit of Haematology Azienda Ospedaliera Papardo Messina Italy
| | - A. Fabbri
- Hematology Unit Azienda Ospedaliero‐Universitaria Senese Siena Italy
| | - G. Pietrantuono
- Hematology and Stem Cell Transplantation Unit IRCCS Centro di Riferimento Oncologico della Basilicata Rionero in Vulture Italy
| | - O. Annibali
- Unit of Haematology and Stem Cell Transplantation Campus Bio‐Medico University Rome Italy
| | - A. Tafuri
- University Hospital Sant'Andrea, Sapienza University of Rome Rome Italy
| | - E. Prete
- Department of Hematology and Bone Marrow Transplant Hospital Card. G. Panico Tricase Italy
| | - A. Mulè
- Division of Hematology, Azienda Villa Sofia‐Cervello Palermo Italy
| | - E. Barbolini
- Gruppo Amici dell'Ematologia GRADE Onlus Foundation Reggio Emilia Italy
| | | | - S. Luminari
- Hematology Unit Azienda Unità Sanitaria Locale ‐ IRCCS Reggio Emilia Italy
| | - F. Merli
- Hematology Unit Azienda Unità Sanitaria Locale ‐ IRCCS Reggio Emilia Italy
| |
Collapse
|
2
|
Ferreri AJ, Tarantino V, Cabras G, Ferrara F, Zinzani PL, Arcaini L, Castellino A, Tucci A, Cocito F, Davies A, Salvador Chalup MM, Cwynarski K, Nogueira FL, Petrucci L, Muzi C, Onofrillo D, Ferrario A, Ramakrishnan P, Scalzulli PR, Tani M, Tisi MC, Papageorgiou SG, Calimeri T, Angelillo P, Foppoli M, Dimou M, Ponzoni M, Iannitto E, Vassilakopoulos TP. PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT. Hematol Oncol 2021. [DOI: 10.1002/hon.66_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- A. J.M. Ferreri
- IRCCS San Raffaele Scientific Institute Lymphoma Unit Dept. of Onco‐Hematology Milano Italy
| | - V. Tarantino
- University of Modena and Reggio Emilia PhD Program in Clinical and Experimental Medicine Modena Italy
| | - G. Cabras
- Ospedale Oncologico Struttura Complessa di Ematologia e CTMO Cagliari Italy
| | - F. Ferrara
- AORN Cardarelli Hospital Division of Hematology and Stem Cell Transplantation Program Naples Italy
| | - P. L. Zinzani
- IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli Bologna Italy
| | - L. Arcaini
- Fondazione IRCCS Policlinico San Matteo & Department of Molecular Medicine University of Pavia Division of Hematology Pavia Italy
| | | | - A. Tucci
- ASST Spedali Civili Hematology Department Brescia Italy
| | - F. Cocito
- ASST‐Monza UC di Ematologia Monza Italy
| | - A. Davies
- CRUK Centre University of Southampton Faculty of Medicine Southampton Experimental Cancer Medicines Centre Southampton UK
| | - M. M.B Salvador Chalup
- Hematológica Oncoclínicas, Hematological Malignancies and Stem Cell Transplantation Belo Horizonte Brazil
| | - K. Cwynarski
- University College London Hospitals Department of Haematology London UK
| | - F. L. Nogueira
- Gurpo Oncoclínicas Clínica Hematologica Belo Horizonte Minas Gerais Brazil
| | - L. Petrucci
- University Sapienza Hematology Department of Translation and Precision Medicine Rome Italy
| | - C. Muzi
- ASST Grande Ospedale Metropolitano Niguarda Division of Haematology Milan Italy
| | - D. Onofrillo
- Spirito Santo Hospital Pediatric Hematology and Oncology Unit Department of Hematology Pescara Italy
| | | | - P. Ramakrishnan
- Harold C. Simmons Comprehensive Cancer Center UT Southwestern Medical Center Division of Hematologic Malignancies and Cellular Therapy Dallas Texas USA
| | - P. R. Scalzulli
- Fondazione IRCCS “Casa Sollievo della Sofferenza” Division of Hematology San Giovanni Rotondo Italy
| | - M. Tani
- Santa Maria delle Croci Hospital Hematology Unit Ravenna Italy
| | - M. C. Tisi
- San Bortolo Hospital Cell Therapy and Hematology Vicenza Italy
| | - S. G. Papageorgiou
- University General Hospital "Attikon" National and Kapodistrian University of Athens Second Department of Internal Medicine Propaedeutic Hematology Unit Athens Greece
| | - T. Calimeri
- IRCCS San Raffaele Scientific Institute Lymphoma Unit Dept. of Onco‐Hematology Milano Italy
| | - P. Angelillo
- IRCCS San Raffaele Scientific Institute Lymphoma Unit Dept. of Onco‐Hematology Milano Italy
| | - M. Foppoli
- IRCCS San Raffaele Scientific Institute Lymphoma Unit Dept. of Onco‐Hematology Milano Italy
| | - M. Dimou
- General Hospital National and Kapodistrian University of Athens First Department of Internal Medicine, Propaedeutic Haematology Clinical Trial Unit Athens Greece
| | - M. Ponzoni
- Università Vita‐salute San Raffaele Milano, Italy Pathology Unit Milan Italy
| | - E. Iannitto
- Casa di Cura "La Maddalena" Hematology and BMT Department of Oncology Palermo Italy
| | - T. P. Vassilakopoulos
- Laikon General Hospital National and Kapodistrian University of Athens Department of Haematology and Bone Marrow Transplantation Athens Greece
| |
Collapse
|
3
|
Greco A, Tonialini L, Scalzulli PR, De Santis G, Prete E, La Rosa E, Cascavilla N, Tarantini G, Pavone V. PIXANTRONE (PIX) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). REAL LIFE EXPERIENCE IN 27 PATIENTS. Hematol Oncol 2021. [DOI: 10.1002/hon.41_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A Greco
- Pia Fondazione Card. G. Panico Hospital, Unit of Hematology Tricase Italy
| | - L Tonialini
- Pia Fondazione Card. G. Panico Hospital, Unit of Hematology Tricase Italy
| | - P. R Scalzulli
- Casa Sollievo della Sofferenza Hospital, Unit of Hematology San Giovanni Rotondo Italy
| | - G De Santis
- Monsignor Raffaele Dimiccoli Hospital, Unit of Hematology Barletta Italy
| | - E Prete
- Pia Fondazione Card. G. Panico Hospital, Unit of Hematology Tricase Italy
| | - E La Rosa
- Pia Fondazione Card. G. Panico Hospital, Unit of Hematology Tricase Italy
| | - N Cascavilla
- Casa Sollievo della Sofferenza Hospital, Unit of Hematology San Giovanni Rotondo Italy
| | - G Tarantini
- Monsignor Raffaele Dimiccoli Hospital, Unit of Hematology Barletta Italy
| | - V Pavone
- Pia Fondazione Card. G. Panico Hospital, Unit of Hematology Tricase Italy
| |
Collapse
|
4
|
Melillo L, Valente D, D'Arena G, Dell'Olio M, Falcone A, Minervini MM, Nobile M, Rossi G, Sanpaolo G, Scalzulli PR, Cascavilla N. Combination treatment of flag with non-pegylated liposomal doxorubicin (MYOCET(TM)) in elderly patients with acute myeloid leukemia: a single center experience. Int J Immunopathol Pharmacol 2011; 24:703-9. [PMID: 21978702 DOI: 10.1177/039463201102400316] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The incidence of acute myeloid leukemia (AML) increases with age, but results of intensive chemotherapy in elderly patients are disappointing. Non-pegylated liposomal formulations of doxorubicin (Myocet™) have been developed with the aim of reducing systemic and cardiac toxicity especially in the elderly. We evaluated the efficacy and toxicity profiles of fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) regimen given in association with Myocet™ in 35 patients with AML, median age 69 years (range 61-83 years). Nineteen (54.3%) had newly-diagnosed AML, twelve (34.3%) patients had secondary AML (ten with Myelodisplastic Syndrome, two with Primary Myelofibrosis) and 4 (11.4%) patients had had a late relapse (>12 months) of AML. Complete remission (CR) and partial remission (PR) were obtained in twenty-two (63%) and 3 (8.5%) patients, respectively. Seven (20%) patients showed a resistant disease. There were 3 early deaths (8.5%). Six patients (17%) experienced severe cardiovascular toxicity. The median overall survival (OS) was 12 months (range 1-52 months) with a median disease-free survival (DFS) of 20 months (range 1-48 months). One-year and two-year DFS were 78.9% and 26.7%, respectively. This study demonstrates that in elderly patients with AML, FLAG-Myocet combination shows promising efficacy response with acceptable toxicity, enabling most patients to receive further treatments, including transplantation procedures.
Collapse
Affiliation(s)
- Lorella Melillo
- Hematology and Stem Cell Transplantation Unit, IRCCS, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Carella AM, Beltrami G, Scalzulli PR, Carella AM, Corsetti MT. Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD). Bone Marrow Transplant 2003; 33:131-2. [PMID: 14566330 DOI: 10.1038/sj.bmt.1704322] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
6
|
Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 2001; 86:44-51. [PMID: 11146570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Recombinant erythropoietin (r-EPO) induces erythroid responses in patients affected by myelodysplastic syndromes (MDS). However, the response rate declines to 10-15% in MDS with substantial transfusion needs. Both in vitro and in vivo studies have suggested that the addition of growth factors (G-CSF, GM-CSF) or interleukin-3 (IL-3) may potentiate the effect of r-EPO on dysplastic erythropoiesis. The aim of this study was to evaluate the effects of the combination of r-EPO with G-CSF, GM-CSF or IL-3 on the anemia of heavily transfusion-dependent MDS patients, previously unresponsive to r-EPO alone. PATIENTS AND METHODS Sixty patients with transfusion-dependent MDS, already treated without significant erythroid response with r-EPO alone, were scheduled to receive, for at least 8 weeks, r-EPO subcutaneously at the dose of 300 U/kg t.i.w. in combination with G-CSF (300 microcg s.c. t.i.w., 27 patients), or GM-CSF (300 microcg s.c. t.i.w., 23 patients), or IL-3 (5 microcg/kg s.c. t.i.w., 10 patients), after a two-week pre-phase during which G-CSF, GM-CSF and IL-3 were administered daily at the same dose, as single drugs. RESULTS Ten patients were not evaluable for erythroid response because of relevant side effects related to GM-CSF or IL-3 administration. Overall, among 50 patients who completed the study, there were 3 erythroid responses (as determined by complete abolition of red-cell transfusions): 1 (4%) in the G-CSF + r-EPO and 2 (10.5%) in the GM-CSF + r-EPO treated groups. No patient responded to the combination of r-EPO + IL-3. All responders had inappropriate serum levels of endogenous EPO and a relatively short disease duration. Both responders to GM-CSF + r-EPO developed acute myeloid leukemia 2-9 months after the start of the combined therapy. A third elderly patient, treated with the same association, developed marrow hypoplasia. A significant increase in leukocyte count occurred in 96% of patients who received r-EPO + G-CSF, 78.9% of those treated with r-EPO + GM-CSF and 66% of subjects receiving r-EPO + IL-3. A significant increase in platelet count was observed in a single patient receiving r-EPO and GM-CSF, while a slight decrease in platelet count with respect to baseline levels occurred in about 20% of patients. INTERPRETATION AND CONCLUSIONS Our results suggest that the combination of r-EPO with G-CSF, GM-CSF or IL-3, at least at the doses and schedules employed in the present study, has limited efficacy on the anemia of heavily transfusion-dependent MDS patients previously unresponsive to r-EPO alone. However, in this setting of patients, the combination of G-CSF or GM-CSF + r-EPO may occasionally be effective in subjects with low circulating levels of serum EPO and short disease duration.
Collapse
Affiliation(s)
- P Musto
- Department of Onco-Hematology, Unit of Hematology, IRCCS Casa Sollievo della Sofferenza, 71013 S. Giovanni Rotondo, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
D'Arena G, Musto P, Di Mauro L, Cascavilla N, Iacono ND, Scalzulli PR, Matera R, Carotenuto M. Predictive parameters for mobilized peripheral blood CD34+ progenitor cell collection in patients with hematological malignancies. Am J Hematol 1998; 58:255-62. [PMID: 9692386 DOI: 10.1002/(sici)1096-8652(199808)58:4<255::aid-ajh1>3.0.co;2-p] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
In order to investigate what is the best single parameter to predict the leukapheretic yield of circulating CD34+ progenitor cells, we retrospectively analyzed data from 68 patients with hematological malignancies who underwent mobilizing therapy. Three main parameters were monitored: total white blood cell (WBC), CD34+ cells, and monocyte counts in peripheral blood (PB) at the same day and at the preceding day of the apheretic procedure. Linear regression analysis revealed a strong correlation between CD34+ cell value in PB just before harvest and the number of CD34+ cells collected (P < 0.0001), but not at the preceding day. Monocyte PB concentration and absolute WBC count did not correlate with CD34+ cells harvested, at the preceding day of leukapheresis as well as at the same day of the procedure. The number of CD34+ cells in mobilized PB at the same day of harvest evidenced a very good capacity of predicting the value of harvested CD34+ cell number after collection, while WBC and monocyte count displayed quite a wide dispersion of results. In particular, an amount greater than 50/microL of circulating CD34+ cells ensured the best collections. Finally, CD34+ and CFU-GM content evaluated for each apheresis showed a strong reciprocal correlation (r 0.78; P < 0.0001). We conclude that the absolute number of CD34+ cells at the day of leukapheresis is the only parameter for identifying the exact timing for apheresis and predicting the amount of peripheral blood progenitor cells (PBPCs) that will be collected. In this setting, WBC and monocyte counts, at the day of collection or at the preceding day, are not useful tools.
Collapse
Affiliation(s)
- G D'Arena
- Division of Hematology, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
| | | | | | | | | | | | | | | |
Collapse
|
8
|
D'Arena G, Musto P, Cascavilla N, Scalzulli PR, Dello Iacono N, Carotenuto M. Circulating CD34+ absolute cell number is the best single parameter to predict the quality of leukapheretic yield. Bone Marrow Transplant 1998; 22:215-6. [PMID: 9707035 DOI: 10.1038/sj.bmt.1701311] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
9
|
Musto P, Falcone A, D'Arena G, Scalzulli PR, Matera R, Minervini MM, Lombardi GF, Modoni S, Longo A, Carotenuto M. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Haematol 1997; 58:314-9. [PMID: 9222286 DOI: 10.1111/j.1600-0609.1997.tb01677.x] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Recombinant erythropoietin (r-EPO) was administered to 37 patients with advanced, transfusion-dependent and chemo-resistant multiple myeloma (MM), at the fixed dose of 10,000/U s.c., 3 times a week, for 2 months. Thirteen patients (35.1%) achieved a significant response in terms of complete abolition of red cell transfusions. Factors significantly predictive of response were: a) inappropriate production of endogenous EPO, as expressed by a reduced observed/predicted ratio; b) presence of a consistent number of circulating erythroid precursors BFU-E; c) low serum levels of tumor necrosis factor (TNF) and interleukin-1 (IL-1), cytokines with inhibitory activity on erythropoiesis; d) a single line of previously received chemotherapy. Renal failure, bone marrow plasma cell infiltration, serum levels of IL-6 and other main clinical and laboratory parameters did not affect significantly the response to r-EPO. High fluorescence reticulocytes (HFR) and soluble transferrin receptor (sTfR) values were useful to detect an early stimulation of erythropoiesis in responders, while a high percentage of circulating hypochromic erythrocytes (HE), as assessed by an automated counter, identified those patients developing functional iron deficiency during r-EPO treatment. We conclude that about one-third of severely anemic patients with advanced MM, unresponsive to chemotherapy, may benefit by r-EPO therapy. The clinical management of these patients can be accomplished using non-invasive parameters, such as sTfR, HFR and HE.
Collapse
Affiliation(s)
- P Musto
- Division of Hematology, IRCCS Casa Sollievo della Sofferenza Hospital S. Giovanni Rotondo, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Musto P, Sajeva MR, Sanpaolo G, D'Arena G, Scalzulli PR, Carotenuto M. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma. Haematologica 1997; 82:354-6. [PMID: 9234591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
The in vitro inhibitory effect of all-trans retinoic acid (ATRA) on myeloma cell growth may be synergistically potentiated by the activity of dexamethasone (DEX) and alpha-interferon (IFN). We treated 10 patients with advanced, refractory multiple myeloma (MM) using a combination of ATRA (100 mg p.o., once a day for two weeks every month), DEX (40 mg i.v., for 4 days every 4 weeks) and IFN (3 MU s.c., three times a week). Eight patients completed at least three months of treatment and were evaluable for response. Two of them showed a partial response which persists after 15 to 17 months. Three patients experienced a stable plateau phase of 4 to +11 months, with a significant improvement in the performance status and bone pain. Progressive disease was seen in the remaining three patients. We conclude that the association of ATRA, DEX and IFN warrants further consideration in MM patients.
Collapse
Affiliation(s)
- P Musto
- Division of Hematology, IRCCS Casa Sollievo della Sofferenza Hospital, S. Giovanni Rotondo, Italy
| | | | | | | | | | | |
Collapse
|
11
|
Scalzulli PR, Musto P, Dell'Olio M, Carotenuto M. CFU-GM are not increased in peripheral blood of patients with chronic lymphocytic leukaemia. Eur J Haematol Suppl 1996; 57:180-1. [PMID: 8856097 DOI: 10.1111/j.1600-0609.1996.tb01358.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
12
|
|